Steven Pipe, MD, Pediatric Hematology & Oncology, Ann Arbor, MI, Michigan Medicine

StevenWPipeMD

Pediatric Hematology & Oncology Ann Arbor, MI

Pediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology

Professor, Pediatrics & Communicable Diseases, University of Michigan Medical School

Dr. Pipe is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pipe's full profile

Already have an account?

Education & Training

  • University of Michigan Hospitals and Health Centers
    University of Michigan Hospitals and Health CentersFELLOWSHIP
  • University of Toronto Faculty of Medicine
    University of Toronto Faculty of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1996 - 2022
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B
    Steven Pipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • #ISTH2020 – Gene Therapy BAY 2599023 Showing Steady FVIII Activity, Safety in Trial
    #ISTH2020 – Gene Therapy BAY 2599023 Showing Steady FVIII Activity, Safety in TrialJuly 25, 2020 11:16
  • AMT-061 Increases FIX Activity, Prevents Bleeds in Severe Hemophilia B Patients, Phase 2b Data Show
    AMT-061 Increases FIX Activity, Prevents Bleeds in Severe Hemophilia B Patients, Phase 2b Data ShowJanuary 16, 2020 08:08
  • uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
    uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene DezaparvovecNovember 16, 2019 02:32
  • Join now to see all

Hospital Affiliations